NanoViricides (NYSE:NNVC) Rating Increased to Strong-Buy at Noble Financial

NanoViricides (NYSE:NNVC) was upgraded by investment analysts at Noble Financial to a “strong-buy” rating in a research note issued on Monday,Zacks.com reports.

NanoViricides Stock Performance

Shares of NanoViricides stock remained flat at $1.50 during trading hours on Monday. The stock had a trading volume of 196,827 shares, compared to its average volume of 579,847. The company has a market cap of $34.47 million, a PE ratio of -2.08 and a beta of 1.67. NanoViricides has a twelve month low of $0.85 and a twelve month high of $2.23. The company’s fifty day simple moving average is $1.45 and its two-hundred day simple moving average is $1.21.

Hedge Funds Weigh In On NanoViricides

Hedge funds have recently bought and sold shares of the company. Armistice Capital LLC purchased a new position in NanoViricides during the 4th quarter valued at about $1,546,000. Jane Street Group LLC acquired a new position in NanoViricides in the 4th quarter valued at about $140,000. Miller Financial Services LLC purchased a new stake in NanoViricides during the fourth quarter worth about $81,000. Geode Capital Management LLC increased its stake in NanoViricides by 9.4% during the fourth quarter. Geode Capital Management LLC now owns 174,371 shares of the company’s stock worth $197,000 after purchasing an additional 14,944 shares during the period. Finally, Susquehanna International Group LLP lifted its position in shares of NanoViricides by 37.4% during the third quarter. Susquehanna International Group LLP now owns 52,217 shares of the company’s stock worth $75,000 after purchasing an additional 14,217 shares in the last quarter. Institutional investors and hedge funds own 10.30% of the company’s stock.

NanoViricides Company Profile

NanoViricides, Inc is a clinical-stage biotechnology company focused on the development of novel antiviral therapies using its proprietary nanomicelle technology. The company designs polymeric, virus-targeted nanoviricides that seek to neutralize viral pathogens by binding to specific viral surface proteins and destroying their structural integrity. NanoViricides’ platform is intended to offer broad-spectrum activity against a range of enveloped viruses, positioning it as a potential solution for both existing and emerging viral threats.

The company’s pipeline includes preclinical and early clinical candidates targeting seasonal and pandemic influenza strains, as well as investigational programs for coronaviruses, hepatitis, dengue, HIV and other viruses.